A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 364 participants.
Also called NCT07923357
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 364 participants
- Registry
-
NCT07923357
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07923357. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-30 (anticipated); primary completion 2027-11-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus (T2DM)
- Condition
- Type 2 Diabetes
- Condition
- T2DM
- Intervention (Drug)
- SAL0150 dose 1
- Intervention (Drug)
- SAL0150 dose 2
- Intervention (Drug)
- SAL0150 dose 2
- Intervention (Drug)
- SAL0150 dose 3
- Intervention (Drug)
- SAL0150 dose 3
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Semaglutide inject 1.0 mg
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Record details
- Record id
cardio:ct-nct07923357- Content hash
7d32616a211c54d8a4e216ddef0a242884a7acd01d96f0b9926c793fe75bec42